Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, was featured in a research report by Encode Ideas L.P., a health care focused research firm. The full research publication is available at https://ibn.fm/NqQs7. The report reads, “Processa’s pipeline is constructed of development-stage assets that have substantial legacy human data, where the company believes a new approach (dosing, indication, trial design, etc.) can unlock latent value. Processa’s management (David Young, Questcor) and board (Khalid Islam, Gentium and Fennec) have a history of successful drug reclamation projects. The company’s lead asset, eniluracil or PCS6422, was a GSK drug that has been studied in over 1,500 cancer patients, where Processa believes slight changes to the dosing regimen and study design can address previous shortcomings. The other pipeline product of note, PCS499, comes from Concert Pharmaceuticals, where it was studied in Ph2 for diabetic nephropathy, but Processa believes it is better suited for a rare dermatology indication, Necrobiosis Lipoidica (‘NL’). We are enthusiastic about both assets, in particular PCS6422, and feel if there is latent value in either or both, this is the team that can unearth it.”
To view the full press release, visit https://ibn.fm/g4iC1
About Processa Pharmaceuticals Inc.
The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with unmet or underserved medical conditions who need treatment options that improve survival and/or quality of life. The company used these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently. Active pipeline programs include: PCS6422 (metastatic colorectal cancer and breast cancer), PCS499 (ulcerative necrobiosis lipoidica) and PCS12852 (GI motility/gastroparesis). The members of the Processa development team have been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and more than 100 FDA meetings throughout their careers. For more information, visit the company’s website at www.ProcessaPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at https://ibn.fm/PCSA
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.